{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:33:38Z","timestamp":1792197218194,"version":"4.4.0"},"reference-count":30,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R01AI179827"],"award-info":[{"award-number":["1R01AI179827"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R21AI148096"],"award-info":[{"award-number":["1R21AI148096"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006501","name":"Cystic Fibrosis Foundation Therapeutics","doi-asserted-by":"publisher","award":["KANT23G0"],"award-info":[{"award-number":["KANT23G0"]}],"id":[{"id":"10.13039\/100006501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2025,10,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Despite the long therapy duration, the treatment outcomes for\n                      <jats:italic toggle=\"yes\">Mycobacterium abscessus<\/jats:italic>\n                      lung disease (MAB-LD) are very poor. \u03b2-Lactams are among the recommended drugs for the treatment of MAB-LD; however, they are prone to hydrolysis by MAB \u03b2-lactamase enzymes. Therefore, \u03b2-lactamase inhibitors have been developed to overcome this problem. Here, we performed minimum inhibitory concentration studies with a reference MAB strain (ATCC19977) and a collection of 63 clinical isolates for penicillin, cephalosporin, and carbapenems alone or in combination with \u03b2-lactamase inhibitors, sulbactam\/durlobactam (Sul\/Dur). There was an average 64-fold (range: 19 to 103) reduction in drugs MIC in the presence of 4 mg\/L Sul\/Dur (1:1 ratio). The fold reduction in MICs was as follows: amoxicillin 94, ceftriaxone 103, cefuroxime 69, cefdinir 19, cefalexin 74, imipenem 23, meropenem 37, tebipenem 89, and faropenem 74. The Sul\/Dur combination also improved the kill effect of the tested \u03b2-lactams by multiple folds as follows: amoxicillin 12.6, ceftriaxone 2,872, cefuroxime 135.5, cefdinir 26.5, cefalexin 1,030, imipenem and meropenem 14, and faropenem 5.5. Since imipenem is already included in the MAB-LD treatment recommendations and ceftriaxone achieves very high lung concentration, we propose to first test these drugs with Sul\/Dur as a double \u03b2-lactam-\u03b2-lactamase backbone regimen to advance the therapy for MAB-LD.\n                    <\/jats:p>\n                    <jats:sec>\n                      <jats:title>IMPORTANCE<\/jats:title>\n                      <jats:p>\n                        \u03b2-Lactams are among the recommended drugs for the treatment of\n                        <jats:italic toggle=\"yes\">Mycobacterium abscessus<\/jats:italic>\n                        lung disease (MAB-LD); however, they are prone to hydrolysis by MAB \u03b2-lactamase enzymes. We show that sulbactam\/durlobactam (Sul\/Dur) can improve the kill effect of several \u03b2-lactam antibiotics that, otherwise, due to observed high minimum inhibitory concentration, deem ineffective. Based on our findings, we propose imipenem that is already included in the MAB-LD treatment recommendations and ceftriaxone that achieves very high lung concentration, to test with Sul\/Dur as a double \u03b2-lactam-\u03b2-lactamase backbone regimen to advance the therapy for MAB-LD.\n                      <\/jats:p>\n                    <\/jats:sec>\n                  <\/jats:sec>","DOI":"10.1128\/spectrum.01492-25","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T13:00:19Z","timestamp":1757509219000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":4,"title":["Sulbactam-durlobactam improves cephalosporin and carbapenem susceptibility and time-kill effect against\n                    <i>Mycobacterium abscessus<\/i>"],"prefix":"10.1128","volume":"13","author":[{"given":"Avneesh","family":"Shrivastava","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01azfw069","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Infectious Diseases, Department of Medicine, University of Texas at Tyler School of Medicine","place":["Tyler, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunavanthi D.","family":"Boorgula","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01azfw069","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Infectious Diseases, Department of Medicine, University of Texas at Tyler School of Medicine","place":["Tyler, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4601-5673","authenticated-orcid":true,"given":"Sanjay","family":"Singh","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01azfw069","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Infectious Diseases, Department of Medicine, University of Texas at Tyler School of Medicine","place":["Tyler, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danaleigh","family":"Stiles","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01azfw069","id-type":"ROR","asserted-by":"publisher"}],"name":"Undergraduate Medical Education, University of Texas at Tyler School of Medicine","place":["Tyler, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1338-1407","authenticated-orcid":true,"given":"Pamela J.","family":"McShane","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01azfw069","id-type":"ROR","asserted-by":"publisher"}],"name":"Section of Pulmonary and Critical Care, Department of Medicine, University of Texas at Tyler School of Medicine","place":["Tyler, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3279-1110","authenticated-orcid":true,"given":"Megan","family":"Devine","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01azfw069","id-type":"ROR","asserted-by":"publisher"}],"name":"Section of Pulmonary and Critical Care, Department of Medicine, University of Texas at Tyler School of Medicine","place":["Tyler, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7592-8012","authenticated-orcid":true,"given":"Tawanda","family":"Gumbo","sequence":"additional","affiliation":[{"name":"IMPI Biotechnology Company Incorporated","place":["Mount Hampden, Zimbabwe"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8786-8851","authenticated-orcid":true,"given":"Shashikant","family":"Srivastava","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01azfw069","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Infectious Diseases, Department of Medicine, University of Texas at Tyler School of Medicine","place":["Tyler, USA"]},{"id":[{"id":"https:\/\/ror.org\/01sps7q28","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Cellular and Molecular Biology, The University of Texas Health Science Centre at Tyler","place":["Tyler, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201909-1874ST"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt410"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200905-0704OC"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq237"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw724"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01206-17"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2016.03.006"},{"key":"e_1_3_4_9_2","unstructured":"No_Author_Listed. 2022. Arixa Pharmaceuticals announces publication of seminal paper demonstrating first oral prodrug of avibactam 2018. Available from: https:\/\/www.biospace.com\/article\/releases\/arixa-pharmaceuticals-announces-publication-of-seminal-paper-demonstrating-first-oral-prodrug-of-avibactam\/. Retrieved 30 Mar 2022."},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz433"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02623-18"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01046-24"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00098-20"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01174-24"},{"key":"e_1_3_4_15_2","volume-title":"XACDURO (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use","author":"No Author Listed","year":"2023","unstructured":"No Author Listed. 2023. XACDURO (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use. 05\/2023 ed. USA Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216974Orig1s000Correctedlbl.pdf.","edition":"05"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae601"},{"key":"e_1_3_4_17_2","volume-title":"CLSI Standard M24","author":"Woods GL","year":"2018","unstructured":"Woods GL, Wengenack NL, Lin G, Brown-Elliott BA, Cirillo DM, Conville PS, Desmond EP, Killian SB, Parrish NM, Pfeltz R, Richter E, Turnidge JD. 2018. Susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes. 3rd ed. CLSI Standard M24. Clinical and Laboratory Standards Institute, Pittsburgh, PA 15264.","edition":"3"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.03529-21"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab535"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad312"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.40993"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2016.0047"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.02273"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02613-18"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01956-20"},{"key":"e_1_3_4_26_2","volume-title":"Public Praises Science; Scientists Fault Public, Media","author":"Leshner AI","year":"2009","unstructured":"Leshner AI. 2009. Scientific achievements less prominent than a decade ago. Public Praises Science; Scientists Fault Public, Media. Pew Research Center for the People & the Press, Washington D.C."},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00609-24"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01174-24"},{"key":"e_1_3_4_29_2","volume-title":"Ceftriaxone for injection, USP","author":"No Author Listed","year":"2013","unstructured":"No Author Listed. 2013. Ceftriaxone for injection, USP. Food and Drug Administration, USA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/065169s022lbl.pdf."},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15616"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01427-21"}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.01492-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.01492-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T13:11:29Z","timestamp":1759842689000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.01492-25"}},"subtitle":[],"editor":[{"given":"Aude A.","family":"Ferran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,7]]}},"alternative-id":["10.1128\/spectrum.01492-25"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.01492-25","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"2025-05-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01492-25"}}